Arizona State Retirement System Has $4.86 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Arizona State Retirement System lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 0.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,456 shares of the medical equipment provider’s stock after acquiring an additional 594 shares during the period. Arizona State Retirement System’s holdings in Hologic were worth $4,863,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. State Street Corp grew its stake in shares of Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after acquiring an additional 81,057 shares during the last quarter. FMR LLC grew its stake in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after acquiring an additional 24,358 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Hologic by 0.7% in the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after acquiring an additional 18,774 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Hologic by 8.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock worth $200,952,000 after acquiring an additional 195,285 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $64.54 on Friday. Hologic, Inc. has a twelve month low of $61.70 and a twelve month high of $84.67. The firm has a market cap of $14.48 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The business has a fifty day moving average of $68.19 and a 200-day moving average of $75.30.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the company. Citigroup reduced their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Finally, Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.